Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Original Research

Validation of Continuous Glucose Monitoring in Children and Adolescents With Cystic Fibrosis

A prospective cohort study

  1. Stephen M.P. O'Riordan, MRCPI, MD1,2,3,4,
  2. Peter Hindmarsh, MD, FRCPCH4,
  3. Nathan R. Hill, DPHIL, MBCS5,6,
  4. David R. Matthews, DPHIL, FRCP5,6,
  5. Sherly George, MSC1,
  6. Peter Greally, MD, FRCPI1,
  7. Gerard Canny, MD, FRCPI2,
  8. Dubhfeasa Slattery, PHD, FRCPI3,
  9. Nuala Murphy, MD, FRCPI3,
  10. Edna Roche, MD, FRCPI1,7,
  11. Colm Costigan, FRCPI2 and
  12. Hilary Hoey, MD, FRCPI1,7
  1. 1National Children's Hospital, Tallaght, Dublin, Ireland;
  2. 2Our Lady's Children's Hospital, Crumlin, Dublin, Ireland;
  3. 3Children's University Hospital, Temple Street, Dublin, Ireland;
  4. 4Institute of Child Health, University College London, Developmental Endocrinology Research Group, London, U.K.;
  5. 5Oxford Centre for Diabetes Endocrinology and Diabetes (OCDEM), Oxford, U.K.;
  6. 6National Institute of Health Research (NIHR), Oxford Biomedical Research Centre, Oxford, U.K.;
  7. 7University of Dublin, Trinity College, Dublin, Ireland.
  1. Corresponding author: Stephen O'Riordan, s.oriordan{at}ich.ucl.ac.uk.
Diabetes Care 2009 Jun; 32(6): 1020-1022. https://doi.org/10.2337/dc08-1925
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

A prospective cohort study

Abstract

OBJECTIVE To validate continuous glucose monitoring (CGM) in children and adolescents with cystic fibrosis.

RESEARCH DESIGN AND METHODS Paired oral glucose tolerance tests (OGTTs) and CGM monitoring was undertaken in 102 children and adolescents with cystic fibrosis (age 9.5–19.0 years) at baseline (CGM1) and after 12 months (CGM2). CGM validity was assessed by reliability, reproducibility, and repeatability.

RESULTS CGM was reliable with a Bland-Altman agreement between CGM and OGTT of 0.81 mmol/l (95% CI for bias ± 2.90 mmol/l) and good correlation between the two (r = 0.74–0.9; P < 0.01). CGM was reproducible with no significant differences in the coefficient of variation of the CGM assessment between visits and repeatable with a mean difference between CGM1 and CGM2 of 0.09 mmol/l (95% CI for difference ± 0.46 mmol/l) and a discriminant ratio of 13.0 and 15.1, respectively.

CONCLUSIONS In this cohort of children and adolescents with cystic fibrosis, CGM performed on two occasions over a 12-month period was reliable, reproducible, and repeatable.

Little is known about the evolution of diabetes and pancreatic disorders in adults with cystic fibrosis (CF) and less in children and adolescents with cystic fibrosis. Patients with CF-related diabetes have a sixfold increase in morbidity and mortality (1). The diagnosis of CF-related diabetes is usually asymptomatic, lying dormant for 2–6 years before diagnosis (1–3). Identification of disordered glucose metabolism before major β-cell loss may be beneficial, since early insulin therapy improves lung function and reduces the number of acute respiratory infections (4,5).

Standard methods of glycemic assessment, random or fasting glucose concentrations, and/or oral glucose tolerance tests (OGTTs) underdiagnose CF-related diabetes (6). Continuous glucose monitoring (CGM) in the normal glucose tolerance (NGT) and impaired glucose tolerance (IGT) stages may allow earlier diagnosis of CF-related diabetes (7), but before this methodology can be applied to children and adolescents with CF, validation is required. Consequently, we have assessed CGM in terms of reliability, repeatability, and reproducibility in 102 children and adolescents with CF on two occasions over 24 months.

RESEARCH DESIGN AND METHODS

A prospective multicenter cohort study of 102 genetically confirmed children and adolescents with CF (48 males, 54 females) aged 9.5–19.0 years was conducted over 24 months. All children underwent “paired testing,” with OGTT and CGM and the initial OGTT used to classify children and adolescents with CF into three groups: NGT, IGT, or CF-related diabetes based on World Health Organization criteria (8). CGM (Medtronic Minimed CGM Gold; Medtronic Diabetes, Watford, U.K.) was recorded at the start of the study (CGM1 visit 1) and after a minimum of 12 months (CGM2 visit 2). Blood glucose concentration was measured using a YSI compatible CX7 Delta Analyzer. After the OGTT was complete, the CGM device remained in situ in the home environment for 72 h on all patients. Patients entered a minimum of four self-monitored blood glucose samples (One Touch Ultra meter; LifeScan, Milpitas, CA) for daily CGM calibration. Ethical approval was obtained from the ethics committees of the three participating hospitals. The study protocol wascarried out in accordance with the Declaration of Helsinki.

Statistical analysis

All data were extracted from the Medtronic Mini Med Solutions CGM sensor, MMT-730 version 3.0c (3.0.128). Mean and SD of the interstitial glucose concentrations for all CGM recordings were derived. Analysis was performed in SPSS version 15.

Validity of CGM in children and adolescents with CF was assessed by determination of reliability, reproducibility, and repeatability. Reliability was assessed by Bland-Altman analysis of agreement (9,10) along with Pearson's correlation coefficient. Reproducibility tested the null hypothesis that the mean difference between the coefficients of variation (CVs) of observations was zero using a paired Student's t test. Repeatability was derived from Bland-Altman analysis and calculation of a discriminant ratio (DR) (11). Data are expressed as mean values with 95% CIs where appropriate. Significance was set at the 5% level.

RESULTS

A total of 104 out of 160 children and adolescents with CF (aged 9.5–19.0 years) were studied. A total of 102 valid CGM results were obtained at CGM1 and 92 at CGM2. The average number of valid CGM sensor readings used was 710 (range 499–1,410).

Mean interstitial CGM glucose for all children and adolescents with CF was 6.7 ± 2.3 mmol/l (means ± SD) on CGM1 and 7.0 ± 2.6 mmol/l CGM2. Mean interstitial CGM glucose for NGT, IGT, and CF-related diabetes is shown in Table 1. All values were significantly higher than in normal healthy nondiabetic subjects (mean 5.1 ± 0.7 mmol/l, P < 0.0001).

View this table:
  • View inline
  • View popup
Table 1

Validity of CGM at visit 1 (CGM1) and visit 2 (CGM2) in 102 children and adolescents with cystic fibrosis (n = 102)

Validitation of CGM in CF

Reliability.

Bland and Altman analysis revealed a mean difference between CGM glucose and OGTT glucose of 0.81 ± 1.47 mmol/l with a 95% CI of the bias ± 2.90 mmol/l. A significant correlation was found between glucose measured by CGM and the blood glucose at five time points in a standard OGTT (r = 0.74–0.91, P < 0.01).

Reproducibility.

Reproducibility was assessed by comparing CVs at five different time points of OGTT and within the subgroups (Table 1). There were no significant differences in the CVs of the CGM assessment between visits, irrespective of glucose tolerance category.

Repeatability.

The mean difference between CGM1 and CGM2 interstitial glucose concentrations was 0.09 ± 2.38 mmol/l with 95% CI for the difference of ± 0.46 mmol/l. The DRs (the variability of an individual to the variability of the group) for CGM1 and CGM2 were 13.0 and 15.1, respectively. Subgroup DRs are shown in Table 1 and indicate that CGM has the ability to identify subjects with high variability, such as CF-related diabetes, within this cohort of children and adolescents with CF.

CONCLUSIONS

This study demonstrates that CGM is a valid method for assessing glycemia in children and adolescents with CF, extending similar observations in adults with CF (7). The validation of CGM in children and adolescents with CF is essential before other prospective research can be undertaken with CGM in children andadolescents with cystic fibrosis and is warrantedbecause of the higher glucose concentrations observed in these patients compared with the general population.

As expected, there was a linear correlation between five-point OGTT plasma blood glucose and the corresponding CGM glucose readings (r = 0.74–0.91). Rather than use correlation or Clarke error grid analysis, which both describe association, we used Bland-Altman analysis of agreement (9,10). The mean difference between the two methods was 0.81 mmol/l with a 95% CI ± 2.90 mmol/l, which is a reasonably acceptable bias for clinical practice.

CGM was reproducible in children with CF with varying degrees of glucose intolerance, since there were no significant differences in the CVs of the CGM assessment between visits, irrespective of diagnosis.

Finally, we have demonstrated that CGM was repeatable as the mean difference between CGM1, and CGM2 was 0.09 mmol/l. Further, all DRs were >1, indicating that CGM has the ability to discriminate between different subjects and allow comparison between subjects.

In conclusion, CGM is a valid measure of glycemia in children and adolescents with CF. These observations suggest that CGM is not influenced by the CF chloride channel defect and has become a useful tool for the assessment of glycemia in children and adolescents with CF.

Acknowledgments

Funding for this study was provided by the Cystic Fibrosis Association of Ireland.

S.O'R. was supported by an European Society for Pediatric Endocrinology ClinicalResearch Fellowship sponsored by Novo Nordisk. No other potential conflicts of interest relevant to this article were reported.

Early parts of this study were presented as oral communications at the 66th Scientific Sessions of the American Diabetes Association, Washington, DC, 9–13 June 2006 and the 43rd Annual Meeting of the European Association for the Study of Diabetes 2007.

Footnotes

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Received October 24, 2008.
    • Accepted March 3, 2009.
  • Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

  • © 2009 by the American Diabetes Association.

References

  1. ↵
    1. Moran A
    : Diagnosis, screening, and management of cystic fibrosis-related diabetes. Curr Diab Rep 2002; 2: 111– 115
    OpenUrlCrossRefPubMed
  2. ↵
    1. Lanng ST,
    2. Nerup B,
    3. Koch JC
    : Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis. Eur J Pediatr 1992; 151: 684– 687
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Finkelstein SM,
    2. Wielinski CL,
    3. Elliott GR,
    4. Warwick WJ,
    5. Barbosa J,
    6. Wu SC,
    7. Klein DJ
    : Diabetes mellitus associated with cystic fibrosis. J Pediatr 1988; 112: 373– 377
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Lanng S,
    2. Thorsteinsson B,
    3. Nerup J,
    4. Koch C
    : Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections. Acta Paediatr 1994; 83: 849– 853
    OpenUrlPubMedWeb of Science
  5. ↵
    1. Dobson L,
    2. Hattersley AT,
    3. Tiley S,
    4. Elworthy S,
    5. Oades PJ,
    6. Sheldon CD
    : Clinical improvement in cystic fibrosis with early insulin treatment. Arch Dis Child 2002; 87: 430– 431
    OpenUrlFREE Full Text
  6. ↵
    1. Dobson L,
    2. Sheldon CD,
    3. Hattersley AT
    : Conventional measures underestimate glycaemia in cystic fibrosis patients. Diabet Med 2004; 21: 691– 696
    OpenUrlCrossRefPubMed
  7. ↵
    1. Dobson L,
    2. Sheldon CD,
    3. Hattersley AT
    : Validation of interstitial fluid continuous glucose monitoring in cystic fibrosis. Diabetes Care 2003; 26: 1940– 1941
    OpenUrlFREE Full Text
  8. ↵
    World Health Organization: Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications Part 1: Diagnosis and Classification of Diabetes Mellitus.WHO/NCD/NCS/99.2, 1999. Diagnostic Criteria for Diabetes Mellitus, Geneva, World Health Organization, 1999
  9. ↵
    1. Bland JM,
    2. Altman DG
    : Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307– 310
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. Bland JM,
    2. Altman DJ
    : Regression analysis. Lancet 1986; 1: 908– 909
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Levy J,
    2. Morris R,
    3. Hammersley M,
    4. Turner R
    : Discrimination, adjusted correlation, and equivalence of imprecise tests: application to glucose tolerance. Am J Physiol 1999; 276: E365– E375
    OpenUrlPubMed
PreviousNext
Back to top
Diabetes Care: 32 (6)

In this Issue

June 2009, 32(6)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Validation of Continuous Glucose Monitoring in Children and Adolescents With Cystic Fibrosis
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Validation of Continuous Glucose Monitoring in Children and Adolescents With Cystic Fibrosis
Stephen M.P. O'Riordan, Peter Hindmarsh, Nathan R. Hill, David R. Matthews, Sherly George, Peter Greally, Gerard Canny, Dubhfeasa Slattery, Nuala Murphy, Edna Roche, Colm Costigan, Hilary Hoey
Diabetes Care Jun 2009, 32 (6) 1020-1022; DOI: 10.2337/dc08-1925

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Validation of Continuous Glucose Monitoring in Children and Adolescents With Cystic Fibrosis
Stephen M.P. O'Riordan, Peter Hindmarsh, Nathan R. Hill, David R. Matthews, Sherly George, Peter Greally, Gerard Canny, Dubhfeasa Slattery, Nuala Murphy, Edna Roche, Colm Costigan, Hilary Hoey
Diabetes Care Jun 2009, 32 (6) 1020-1022; DOI: 10.2337/dc08-1925
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • CONCLUSIONS
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

Original Research

  • Risk Factors for Longitudinal Resting Heart Rate and Its Associations With Cardiovascular Outcomes in the DCCT/EDIC Study
  • An Age-Related Exponential Decline in the Risk of Multiple Islet Autoantibody Seroconversion During Childhood
  • Association of Implementation of a Comprehensive Preconception-to-Pregnancy Management Plan With Pregnancy Outcomes Among Chinese Pregnant Women With Type 1 Diabetes: The CARNATION Study
Show more Original Research

Clinical Care/Education/Nutrition/Psychosocial Research

  • Not Only Diabetes but Also Prediabetes Leads to Functional Decline and Disability in Older Adults
  • Specific Dimensions of Depression Have Different Associations With Cognitive Decline in Older Adults With Type 2 Diabetes
  • Novel Biochemical Markers of Glycemia to Predict Pregnancy Outcomes in Women With Type 1 Diabetes
Show more Clinical Care/Education/Nutrition/Psychosocial Research

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.